Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DYNE-101 phase 3 placebo-controlled study in myotonic dystrophy type 1
jRCT2051260017Phase 3Recruiting
- Sponsor
- Dyne Therapeutics
- Start
- Apr 2026
- Modality
- Antibody Conjugates → Antibody-Based Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in myotonic dystrophy type 1 (DM1) comparing DYNE-101 with Placebo (2 arms). Primary endpoint: 5 times sit to stand time. Started Apr 2026; status: recruiting.
02
Drugs
zeleciment basivarsen
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on jRCT2051260017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260017.